Bowel cancer “melted away” after immunotherapy, then stayed away #Science #HealthandMedicine #Oncology #immunotherapy #bowelcancer #neoprismcrc #cancerresearch #pembrolizumab
@purescience.news
@purescience.newsBowel cancer “melted away” after immunotherapy, then stayed away #Science #HealthandMedicine #Oncology #immunotherapy #bowelcancer #neoprismcrc #cancerresearch #pembrolizumab
@natcomms.nature.comResults from an open label, multicenter phase I #trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of #ASTX660 in combination with the anti-PD-1 antibody #pembrolizumab for solid #tumors doi.org/10.1038/s414...
@shinyblackshoe.bsky.socialSpeaking of nice posters... Poster 113 describing sub cut #pembrolizumab visually caught my eye. If you are designing a poster it may be worth taking a look to get some ideas about clean lines, white space etc.
@jamaoncology.comIn #HPV16-positive recurrent or metastatic #HeadAndNeckCancer, PDS0101 plus #Pembrolizumab showed antitumor activity and manageable safety in immune checkpoint inhibitor–naive patients, but no objective responses in resistant patients. ja.ma/4xVtvql
@ipharmaservices.bsky.socialPh3 DESTINY-Lung04: #Enhertu erzielt 14,3 Mo. mPFS vs. 8,3 Mo. mit #Pembrolizumab + Chemo bei 1L HER2-mutiertem #NSCLC (37% geringeres Risiko Progress/Tod).
www.ipharmacenter.com/post/iaslc-2...
#WCLC2026 #WCLC26
@ipharmaservices.bsky.socialDESTINY-Lung04 (Ph3) : #Enhertu atteint 14,3 m de SSP vs 8,3 m sous #pembrolizumab + chimio en 1L dans le #CPNPC muté HER2 (-37% risque décès/progression)
www.ipharmacenter.com/post/iaslc-2...
#WCLC2026 #WCLC26 #Oncologie
@ipharmaservices.bsky.social#Enhertu alcanzó 14,3 meses de mediana de SLP vs 8,3 meses con #pembrolizumab + quimio en 1L para #CPCNP con mutación HER2
www.ipharmacenter.com/post/iaslc-2...
#WCLC2026 #WCLC26 #Oncología
@newsen.bsky.socialPromising Survival Results for Ivonescimab Over Pembrolizumab in NSCLC Treatment at WCLC 2026 #None #Hong_Kong #Akeso #Ivonescimab #Pembrolizumab
@newsen.bsky.socialLatest Findings on Sacituzumab Govitecan and Pembrolizumab in Treating NSCLC Fail to Show Significant Progress #South_Korea #Seoul #Sacituzumab #NSCLC #Pembrolizumab
@newsen.bsky.socialSignificant Survival Advantage of Ivonescimab Over Pembrolizumab in NSCLC: HARMONi-2 Study Insights #None #Akeso #Ivonescimab #Pembrolizumab
@jamaoncology.comIn persistent, recurrent, or metastatic #CervicalCancer, first-line #Pembrolizumab plus chemotherapy with or without bevacizumab maintained overall survival and progression-free survival benefit at 5 years, with no new safety signals observed. ja.ma/3UHjheC
@nikolospharma.bsky.social
@newsen.bsky.socialGroundbreaking Approval for Lifesaving Treatment in Europe for TNBC Patients #None #Sacituzumab #TNBC #Pembrolizumab